Now the question efficacy - the FX trial failed. What is difference between efficacy indications for FX and CX? Why CX is supposed to succeed when FX failed - same drug, same target organ and advanced form of disease?
So yes - the efficacy is what matters.
With the possible downside - one should consider Jan 2018 options